Pages that link to "Q84920371"

The following pages link to The first use of an investigational multicomponent meningococcal serogroup B vaccine (4CMenB) in humans (Q84920371):

Displaying 35 items.

• Vaccination with a multicomponent meningococcal B vaccine in prevention of disease in adolescents and young adults (Q26799455) (← links)
• Role of factor H binding protein in Neisseria meningitidis virulence and its potential as a vaccine candidate to broadly protect against meningococcal disease (Q26995760) (← links)
• Molecular and serological diversity of Neisseria meningitidis carrier strains isolated from Italian students aged 14 to 22 years. (Q33703560) (← links)
• LOS oligosaccharide modification enhances dendritic cell responses to meningococcal native outer membrane vesicles expressing a non-toxic lipid A (Q34376049) (← links)
• Persistence of specific bactericidal antibodies at 5 years of age after vaccination against serogroup B meningococcus in infancy and at 40 months. (Q35463235) (← links)
• Thinking globally, acting locally: harnessing the immune system to deal with recalcitrant pathogens. (Q35620188) (← links)
• Extensive genomic variation within clonal complexes of Neisseria meningitidis. (Q35623008) (← links)
• Proteomic analysis and immunogenicity of Mannheimia haemolytica vesicles (Q36606754) (← links)
• Importance of inhibition of binding of complement factor H for serum bactericidal antibody responses to meningococcal factor H-binding protein vaccines (Q37037083) (← links)
• Homologous recombination drives both sequence diversity and gene content variation in Neisseria meningitidis. (Q37208928) (← links)
• A multi-component meningococcal serogroup B vaccine (4CMenB): the clinical development program (Q37471668) (← links)
• Immunogenicity and safety among laboratory workers vaccinated with Bexsero® vaccine (Q37713758) (← links)
• Immunization update IV. (Q38134463) (← links)
• A vaccine against serogroup B Neisseria meningitidis: dealing with uncertainty (Q38200261) (← links)
• Use of Serogroup B Meningococcal Vaccines in Persons Aged ≥10 Years at Increased Risk for Serogroup B Meningococcal Disease: Recommendations of the Advisory Committee on Immunization Practices, 2015. (Q38525922) (← links)
• Serum bactericidal antibody assays - The role of complement in infection and immunity (Q38549601) (← links)
• Safety Profile and Immunologic Responses of a Novel Vaccine Against Shigella sonnei Administered Intramuscularly, Intradermally and Intranasally: Results From Two Parallel Randomized Phase 1 Clinical Studies in Healthy Adult Volunteers in Europe. (Q38665950) (← links)
• Identification of potential vaccine candidates against Streptococcus pneumoniae by reverse vaccinology approach (Q39259375) (← links)
• Vaccines, reverse vaccinology, and bacterial pathogenesis (Q39426398) (← links)
• Comparative study of the vaccine potential of six outer membrane proteins of Edwardsiella tarda and the immune responses of flounder (Paralichthys olivaceus) after vaccination (Q40315777) (← links)
• Immune responses to a recombinant, four-component, meningococcal serogroup B vaccine (4CMenB) in adolescents: a phase III, randomized, multicentre, lot-to-lot consistency study. (Q41077558) (← links)
• A comparative evaluation of two investigational meningococcal ABCWY vaccine formulations: Results of a phase 2 randomized, controlled trial. (Q41400370) (← links)
• Expression of human CEACAM1 in transgenic mice limits the Opa-specific immune response against meningococcal outer membrane vesicles. (Q42251621) (← links)
• Outcomes of invasive meningococcal serogroup B disease in children and adolescents (MOSAIC): a case-control study. (Q45897656) (← links)
• A Burkholderia pseudomallei Outer Membrane Vesicle Vaccine Provides Cross Protection against Inhalational Glanders in Mice and Non-Human Primates. (Q46242885) (← links)
• Immunogenicity and safety of the multicomponent meningococcal B vaccine (4CMenB) in children and adolescents: a systematic review and meta-analysis (Q47547042) (← links)
• Prevalence and genetic characteristics of 4CMenB and rLP2086 vaccine candidates among Neisseria meningitidis serogroup B strains, China. (Q52361221) (← links)
• Global epidemiology of serogroup B meningococcal disease and opportunities for prevention with novel recombinant protein vaccines. (Q54233532) (← links)
• Four-year antibody persistence and response to a booster dose of a pentavalent MenABCWY vaccine administered to healthy adolescents and young adults. (Q55021359) (← links)
• A bivalent Neisseria meningitidis recombinant lipidated factor H binding protein vaccine in young adults: Results of a randomised, controlled, dose-escalation phase 1 trial (Q57588792) (← links)
• The Development of a Vaccine Against Meningococcus B Using Reverse Vaccinology (Q64108196) (← links)
• Short-term safety of 4CMenB vaccine during a mass meningococcal B vaccination campaign in Quebec, Canada (Q64135617) (← links)
• [From a pathogen's genome to an effective vaccine: the four-component meningococcal serogroup B vaccine] (Q92426572) (← links)
• Broad vaccine protection against Neisseria meningitidis using factor H binding protein (Q98905790) (← links)
• Immunological fingerprint of 4CMenB recombinant antigens via protein microarray reveals key immunosignatures correlating with bactericidal activity (Q100454918) (← links)